Previous Close | 16.53 |
Open | 16.71 |
Bid | 17.40 x 200 |
Ask | 17.53 x 200 |
Day's Range | 16.50 - 17.76 |
52 Week Range | 8.08 - 41.45 |
Volume | |
Avg. Volume | 278,729 |
Market Cap | 369.384M |
Beta (5Y Monthly) | 0.44 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -6.57 |
Earnings Date | May 06, 2024 - May 10, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 22.29 |
Subscribe to Yahoo Finance Plus to view Fair Value for ENTA
WATERTOWN, Mass., March 06, 2024--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at Leerink Partners Global Biopharma Conference on March 13, 2024 at 10:40 a.m. ET in Miami, FL.
The analysts might have been a bit too bullish on Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ), given that the company...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2024 Earnings Call Transcript February 7, 2024 Enanta Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to Enanta Pharmaceuticals’ Fiscal First Quarter Financial Results Conference Call. At this time, […]